The European Association of Nuclear Medicine (EANM) and Nuclear Medicine Europe express disappointment over the recent European Parliament vote on the Pharmaceutical Regulation and Directive, which did not incorporate their proposed amendments aimed at updating the regulatory framework for radiopharmaceuticals.
Despite the pivotal role Nuclear Medicine plays in modern healthcare, especially in cancer care as recognized by EU initiatives like the SAMIRA Action Plan, the current legislative approach fails to acknowledge the significant advancements in radiopharmaceuticals since 2004. This oversight poses challenges to the industry and clinical sectors, leading to uncertainties and reduced availability of radiopharmaceuticals across Europe.
EANM and Nuclear Medicine Europe advocate for a regulatory framework that aligns with the evolving landscape of Nuclear Medicine, emphasizing the need for updated definitions and provisions to support the growth and accessibility of radiopharmaceuticals. They call upon policymakers to reconsider these developments and ensure that the revised legislation reflects the advancements in Nuclear Medicine, ultimately benefiting patients across the EU.